Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research
/in Cervical Cancer, Dendritic Cells, International Publications /von 2016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e51Oncolytic virotherapy for urological cancers
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-52Dr. Dirk Lorenzen stellt IOZK Immuntherapie in Shengzhou und Shanghai vor
/in IOZK Meldungen /von IOZKIn Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth
/in Colorectal Cancer, Hyperthermia, International Publications /von 2016-05-14 / Cancers (Basel) 2016 May;8(5)Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
/in International Publications, Newcastle Disease Virus /von 2016-05-12 / J. Virol. 2016 06;90(11):5343-5352Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy
/in International Publications, Newcastle Disease Virus /von 2016-05-07 / Virus Res. 2016 08;221:23-9Dendritic cell-based cancer immunotherapy for colorectal cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-86Cancer Vaccines in Ovarian Cancer: How Can We Improve?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2016-05-03 / Biomedicines 2016 May;4(2)Veröffentlichung von Stefaan Van Gool MD. PhD.: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZK
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de